Our Story
Founded in 2010, Huiyu Pharmaceuticals has established itself as a global pharmaceutical company dedicated to anti-cancer drug development and manufacturing. Its R&D is focused on innovative drug development in various modalities including generics, and innovative small molecule and biopharmaceutical therapies.
Its R&D headquarters is located in the Chengdu Tianfu International Bio-City, while its global footprint extends through subsidiaries located in the United States, the United Kingdom, and Europe.
Internationally, Huiyu Pharmaceuticals has earned GMP certifications from a wide array of regulatory bodies, including China, the United Kingdom, Finland, as well as 27 EU member states and 53 Commonwealth nations. In 2022, the company successfully passed the US FDA's on-site certification, aligning its production quality management system with the stringent international standards set by China, the EU, and the United States.
In 2015, its wholly-owned subsidiary, British Huiyu Pharmaceuticals, was awarded the EU drug release qualification certification, paving the way for its brand of anti-cancer injections to achieve large-scale sales across the European Union. The company boasts over 300 overseas approval documents, either owned or through authorized partners, and has forged cooperation agreements in nearly 100 countries. In the United Kingdom, Huiyu Pharmaceuticals has secured marketing approval for 16 leading anti-cancer injections and 2 other pharmaceuticals preparations, which are now available in over 1,300 medical institutions worldwide.
On October 26, 2021, Huiyu Pharmaceuticals made its debut on the Science and Technology Innovation Board, cementing its status as an innovative pharmaceutical company with a global vision. Currently, the company's portfolio includes 21 approved drugs for marketing. Notably, many of these drugs are among the first or the top three to be reviewed and approved, showcasing Huiyu's commitment to innovation and excellence in the pharmaceutical industry.
Huiyu Pharmaceuticals’ GMP manufacturing facility spans an impressive 160 acres, featuring a comprehensive setup that includes 8 production units, alongside dedicated areas for quality control and administrative functions. Notably, the quality control and inspection center alone cover nearly 3,000 square meters and is equipped with over 50 laboratories, underscoring the company's commitment to maintaining the highest standards of product quality and safety.
In addition to its current capabilities, Huiyu Pharmaceutical is on the verge of completing its EU standard injection production facility. This expansion will introduce 9 injection production laboratories and 3 state-of-the-art, fully automated packaging laboratories, significantly enhancing the company’s production efficiency and capacity for injectable drugs. The development of 8 Active Pharmaceutical Ingredient (API) production laboratories has completion. This section will feature automated production laboratories, a quality control center, a warehouse, and other essential supporting facilities. This expansion not only augments Huiyu Pharmaceutical's manufacturing capabilities but also reinforces its position as a leading player in the pharmaceutical industry, with a solid foundation for innovation, quality, and global market reach.
Innovative
Therapeutic
R&D
Generic Medicine
CDMO/CMO
Partnering
Investors
Contact Us
